Viveve Medical Inc (NASDAQ:VIVE) Expected to Post Quarterly Sales of $3.29 Million
Equities analysts expect Viveve Medical Inc (NASDAQ:VIVE) to report $3.29 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Viveve Medical’s earnings, with estimates ranging from $3.13 million to $3.57 million. Viveve Medical posted sales of $1.56 million during the same quarter last year, which suggests a positive year over year growth rate of 110.9%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 10th.
According to Zacks, analysts expect that Viveve Medical will report full-year sales of $3.29 million for the current fiscal year, with estimates ranging from $14.82 million to $16.00 million. For the next financial year, analysts expect that the business will post sales of $25.00 million per share, with estimates ranging from $21.36 million to $28.20 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.06. Viveve Medical had a negative net margin of 220.16% and a negative return on equity of 220.38%. The business had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.70 million.
A number of analysts recently commented on VIVE shares. ValuEngine upgraded Viveve Medical from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Raymond James Financial, Inc. initiated coverage on Viveve Medical in a research report on Thursday, May 25th. They set an “outperform” rating and a $10.00 target price for the company. Cowen and Company initiated coverage on Viveve Medical in a research report on Wednesday, May 3rd. They set an “outperform” rating and a $11.00 target price for the company. Finally, B. Riley restated a “buy” rating and set a $10.00 target price on shares of Viveve Medical in a research report on Wednesday, May 17th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $13.25.
COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/07/viveve-medical-inc-nasdaqvive-expected-to-post-quarterly-sales-of-3-29-million-updated-updated-updated.html.
Several institutional investors have recently modified their holdings of VIVE. Stonepine Capital Management LLC raised its position in shares of Viveve Medical by 48.1% in the first quarter. Stonepine Capital Management LLC now owns 3,849,711 shares of the company’s stock valued at $24,256,000 after buying an additional 1,250,000 shares in the last quarter. HighTower Advisors LLC boosted its stake in Viveve Medical by 36.9% in the first quarter. HighTower Advisors LLC now owns 1,293,718 shares of the company’s stock valued at $8,192,000 after buying an additional 348,682 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in Viveve Medical during the first quarter valued at approximately $5,942,000. Wexford Capital LP boosted its stake in Viveve Medical by 23.9% in the first quarter. Wexford Capital LP now owns 777,124 shares of the company’s stock valued at $4,919,000 after buying an additional 150,000 shares during the last quarter. Finally, Granahan Investment Management Inc. MA boosted its stake in Viveve Medical by 8.0% in the first quarter. Granahan Investment Management Inc. MA now owns 396,494 shares of the company’s stock valued at $2,510,000 after buying an additional 29,364 shares during the last quarter. Institutional investors and hedge funds own 60.85% of the company’s stock.
Viveve Medical (VIVE) traded up 2.90% during trading on Friday, hitting $7.45. 66,714 shares of the stock traded hands. The firm’s 50-day moving average is $7.57 and its 200 day moving average is $6.07. Viveve Medical has a 52 week low of $3.75 and a 52 week high of $11.16. The stock’s market cap is $144.19 million.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Viveve Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc and related stocks with our FREE daily email newsletter.